Ranbaxy Laboratories rose 2.05% to Rs 328.35 at 12:14 IST on BSE after the company reported a consolidated net loss of Rs 158.94 crore for Q4 December 2013, lower than net loss of Rs 492.44 crore in Q4 December 2012.
The Q4 result was announced during trading hours today, 5 February 2014.
Meanwhile, the S&P BSE Sensex was down 16.35 points or 0.08% at 20,195.58.
On BSE, so far 7.37 lakh shares were traded in the counter as against average daily volume of 5.51 lakh shares in the past one quarter.
The stock was volatile. The stock rose as much as 3.8% at the day's high of Rs 334 so far during the day. The stock lost as much as 1.28% at the day's low of Rs 317.60 so far during the day. The stock had hit a 52-week high of Rs 490.15 on 6 January 2014. The stock had hit a 52-week low of Rs 253.95 on 2 August 2013.
The stock had underperformed the market over the past one month till 4 February 2014, sliding 32.79% compared with Sensex's 3.07% fall. The scrip had also underperformed the market in past one quarter, declining 21.85% as against Sensex's 4.84% fall.
The large-cap company has equity capital of Rs 211.89 crore. Face value per share is Rs 5.
Ranbaxy Laboratories' consolidated total income rose 5.06% to Rs 2929.23 crore in Q4 December 2013 over Q4 December 2012.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of generic medicines. Ranbaxy is a member of the Daiichi Sankyo Group.
Powered by Capital Market - Live News
